Analysis of Anti-Vascular Endothelial Growth Factor Injection Claims Data in US Medicare Part B Beneficiaries From 2012 to 2015.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2019.1971
Abstract: Importance The frequency of anti-vascular endothelial growth factor (VEGF) injections has grown exponentially with the introduction of bevacizumab, ranibizumab, and most recently aflibercept. The cost associated with these medications has garnered significant national attention, warranting… read more here.
Keywords: part beneficiaries; bevacizumab; part; 2012 2015 ... See more keywords
Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions.
Sign Up to like & getrecommendations! Published in 2022 at "Health affairs"
DOI: 10.1377/hlthaff.2021.01742
Abstract: For high-price drugs, Medicare Part D beneficiaries who do not receive a low-income subsidy must pay a percentage of the drug's price for each medication fill. Without that subsidy, which lowers out-of-pocket spending, beneficiaries typically… read more here.
Keywords: many medicare; high price; part beneficiaries; price ... See more keywords